http://www.prnewswire.com/rss/health/clinical-trials-medial-discoveries-news.rss/ Press Releases from PR Newswire about Clinical Trials & Medical Discoveries en-us Wed, 12 Jul 2017 23:45:33 EDT Wed, 12 Jul 2017 20:15:00 EDT http://www.prnewswire.com/news-releases/global-clinical-trial-supply-and-logistics-market-for-pharma-2017-2027-300487508.html http://www.prnewswire.com/news-releases/global-clinical-trial-supply-and-logistics-market-for-pharma-2017-2027-300487508.html Wed, 12 Jul 2017 20:15:00 EDT LONDON, July 12, 2017 /PRNewswire/ -- Report Details The Global Clinical Trial Supply and Logistics Market is expected to grow at a CAGR of 7.0% from 2016-2021 and CAGR of 5.6% from 2021-2027. The market is expected to grow at a CAGR of 6.2% from 2016 to 2027. The market is estimated...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma-300487224.html http://www.prnewswire.com/news-releases/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma-300487224.html Wed, 12 Jul 2017 16:00:00 EDT THOUSAND OAKS, Calif., July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of overall survival (OS), demonstrating that KYPROLIS® (carfilzomib), lenalidomide and...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/the-feinstein-institute-and-applied-immunotherapeutics-inc-agree-to-develop-new-anti-inflammatory-treatments-for-autoimmune-disease-300487098.html http://www.prnewswire.com/news-releases/the-feinstein-institute-and-applied-immunotherapeutics-inc-agree-to-develop-new-anti-inflammatory-treatments-for-autoimmune-disease-300487098.html Wed, 12 Jul 2017 12:45:00 EDT MANHASSET, N.Y., July 12, 2017 /PRNewswire-USNewswire/ -- The Feinstein Institute for Medical Research at Northwell Health announced that it has agreed to license the rights to breakthrough discoveries in treating inflammation, as well as specific antibodies and drug candidates, to...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/the-garfield-vte-registrys-first-ever-results-presented-at-the-isth-2017-congress-shed-light-on-a-wide-heterogeneity-of-vte-patients-across-the-globe-their-treatment-and-outcomes-634063303.html http://www.prnewswire.com/news-releases/the-garfield-vte-registrys-first-ever-results-presented-at-the-isth-2017-congress-shed-light-on-a-wide-heterogeneity-of-vte-patients-across-the-globe-their-treatment-and-outcomes-634063303.html Wed, 12 Jul 2017 10:25:00 EDT en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/new-study-finds-no-additional-benefit-from-rs-meso-zeaxanthin-300486958.html http://www.prnewswire.com/news-releases/new-study-finds-no-additional-benefit-from-rs-meso-zeaxanthin-300486958.html Wed, 12 Jul 2017 10:00:00 EDT DES MOINES, Iowa, July 12, 2017 /PRNewswire/ -- A study by co-author John Nolan, PhD, of the Macular Pigment Research Group at Waterford Institute of Technology and presented at the 18th International Symposium on Carotenoids in Lucerne, Switzerland, showed that the addition of (RS)...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/new-data-demonstrate-prophylactic-treatment-with-idelvion-reduces-bleed-frequency-and-has-potential-to-positively-impact-patients-with-haemophilia-b-300486914.html http://www.prnewswire.com/news-releases/new-data-demonstrate-prophylactic-treatment-with-idelvion-reduces-bleed-frequency-and-has-potential-to-positively-impact-patients-with-haemophilia-b-300486914.html Wed, 12 Jul 2017 09:00:00 EDT BERLIN, July 12, 2017 /PRNewswire/ -- CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low bleeding rates in both adult and paediatric patients with haemophilia B. Results were presented at the...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/eli-lilly-and-company-to-present-more-than-40-abstracts-at-the-alzheimers-association-international-conference-2017-aaic-2017-300486913.html http://www.prnewswire.com/news-releases/eli-lilly-and-company-to-present-more-than-40-abstracts-at-the-alzheimers-association-international-conference-2017-aaic-2017-300486913.html Wed, 12 Jul 2017 09:00:00 EDT Data highlights include important health outcomes data emphasizing the need for timely detection and management of Alzheimer's disease INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present findings from more than 40 research...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/new-research-finds-earlysenses-contact-free-sensor-accurately-detects-sleep-apnea-and-disordered-breathing-in-children-634045413.html http://www.prnewswire.com/news-releases/new-research-finds-earlysenses-contact-free-sensor-accurately-detects-sleep-apnea-and-disordered-breathing-in-children-634045413.html Wed, 12 Jul 2017 09:00:00 EDT en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/astrocytic-gene-in-the-brain-determines-the-language-learning-ability-of-humans-300486790.html http://www.prnewswire.com/news-releases/astrocytic-gene-in-the-brain-determines-the-language-learning-ability-of-humans-300486790.html Wed, 12 Jul 2017 09:00:00 EDT - Collaboration of KIST-Ewha Womans University identified that the astrocytic gene affect changes in brain size and cognitive function. - The genetic variation on astrocyte water channel, aquaporin-4, determines language ability. SEOUL, South Korea, July 12, 2017 /PRNewswire/--...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/qr-pharma-inc-presents-new-data-on-posiphen-in-down-syndrome-at-the-alzheimers-disease-international-conference-aaic-2017-london-300486795.html http://www.prnewswire.com/news-releases/qr-pharma-inc-presents-new-data-on-posiphen-in-down-syndrome-at-the-alzheimers-disease-international-conference-aaic-2017-london-300486795.html Wed, 12 Jul 2017 08:30:00 EDT BERWYN, Pa., July 12, 2017 /PRNewswire/ -- QR Pharma, Inc., a privately held phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer's (AD), Parkinson's (PD) and other neurodegenerative diseases, today announced the presentation at AAIC London of its...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/playing-it-safe-in-quest-to-improve-patient-outcomes-hospitals-use-biomarkers-to-gauge-patient-risk-for-acute-kidney-injury-300486738.html http://www.prnewswire.com/news-releases/playing-it-safe-in-quest-to-improve-patient-outcomes-hospitals-use-biomarkers-to-gauge-patient-risk-for-acute-kidney-injury-300486738.html Wed, 12 Jul 2017 08:30:00 EDT SAN DIEGO, July 12, 2017 /PRNewswire/ -- For critically ill hospital patients, no matter what the primary health problem, one of the most serious and frequent complications clinicians worry about is acute kidney injury, which is damage to the kidneys that impairs their ability to clear...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/bio-products-laboratory-presents-new-phase-3-data-demonstrating-prophylactic-coagadex-coagulation-factor-x-human-dosing-prevents-or-reduces-bleeding-episodes-in-children-with-moderate-to-severe-hereditary-factor-x-deficiency-300486917.html http://www.prnewswire.com/news-releases/bio-products-laboratory-presents-new-phase-3-data-demonstrating-prophylactic-coagadex-coagulation-factor-x-human-dosing-prevents-or-reduces-bleeding-episodes-in-children-with-moderate-to-severe-hereditary-factor-x-deficiency-300486917.html Wed, 12 Jul 2017 08:15:00 EDT ELSTREE, England and DURHAM, N.C., July 12, 2017 /PRNewswire/ -- Bio Products Laboratory Limited (BPL), a leading manufacturer of plasma-derived protein therapies, presented this week new data from TEN02, the Phase 3, prospective study of Coagadex® (Coagulation Factor X, Human) for...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/regen-biopharma-inc-researchers-discover-new-dynamic-compound-which-modulates-the-nr2f6-checkpoint-634033903.html http://www.prnewswire.com/news-releases/regen-biopharma-inc-researchers-discover-new-dynamic-compound-which-modulates-the-nr2f6-checkpoint-634033903.html Wed, 12 Jul 2017 08:00:00 EDT en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/neuraltus-announces-completion-of-enrollment-in-confirmatory-phase-2-study-of-np001-in-als-patients-with-systemic-inflammation-300486740.html http://www.prnewswire.com/news-releases/neuraltus-announces-completion-of-enrollment-in-confirmatory-phase-2-study-of-np001-in-als-patients-with-systemic-inflammation-300486740.html Wed, 12 Jul 2017 08:00:00 EDT SAN BRUNO, Calif., July 12, 2017 /PRNewswire/ -- Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases, announced that it has completed enrollment of 138 patients with amyotrophic late...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/le-moustique-friendly-aedes-doxitec-recoit-une-evaluation-positive-pour-la-norme-europeenne-en-matiere-de-sante-humaine-et-denvironnement-634029303.html http://www.prnewswire.com/news-releases/le-moustique-friendly-aedes-doxitec-recoit-une-evaluation-positive-pour-la-norme-europeenne-en-matiere-de-sante-humaine-et-denvironnement-634029303.html Wed, 12 Jul 2017 07:30:00 EDT OXFORD, Angleterre, July 12, 2017 /PRNewswire/ -- Le RIVM conclut à un risque négligeable concernant les moustiques  Friendly™ Aedes d'Oxitec   Le Haut Conseil des biotechnologies en France fait également part de son soutien dans une publication   L'Institut natio...

]]>

]]> PRNewswire fr PR Newswire Association LLC. http://www.prnewswire.com/news-releases/viking-therapeutics-completes-enrollment-in-phase-2-study-of-vk5211-in-patients-recovering-from-hip-fracture-300486755.html http://www.prnewswire.com/news-releases/viking-therapeutics-completes-enrollment-in-phase-2-study-of-vk5211-in-patients-recovering-from-hip-fracture-300486755.html Wed, 12 Jul 2017 07:00:00 EDT SAN DIEGO, July 12, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that enrollment has been completed in the company's...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/asterias-biotherapeutics-completes-enrollment-and-dosing-of-scistar-studys-ais-b-10-million-cell-cohort-300486753.html http://www.prnewswire.com/news-releases/asterias-biotherapeutics-completes-enrollment-and-dosing-of-scistar-studys-ais-b-10-million-cell-cohort-300486753.html Wed, 12 Jul 2017 07:00:00 EDT FREMONT, Calif., July 12, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced completion of enrollment and dosing of the AIS-B 10 million cell cohort in the company's ongoing SCiStar...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/ru-634022363.html http://www.prnewswire.com/news-releases/ru-634022363.html Wed, 12 Jul 2017 06:46:00 EDT ru PR Newswire Association LLC. http://www.prnewswire.com/news-releases/missouri-is-the-first-state-to-institute-newborn-screening-for-spinal-muscular-atrophy-300486375.html http://www.prnewswire.com/news-releases/missouri-is-the-first-state-to-institute-newborn-screening-for-spinal-muscular-atrophy-300486375.html Tue, 11 Jul 2017 14:01:00 EDT CHICAGO, July 11, 2017 /PRNewswire/ -- Governor Eric Greitens today signed into law Senate Bill 50, instituting newborn screening for spinal muscular atrophy (SMA). The bill will make Missouri the first state in the country to screen all newborns for SMA, the leading genetic cause of...

]]>

]]> PRNewswire en-US PR Newswire Association LLC. http://www.prnewswire.com/news-releases/removing-blue-from-led-light-at-night-may-reduce-obesity-and-diabetes-risk-300486303.html http://www.prnewswire.com/news-releases/removing-blue-from-led-light-at-night-may-reduce-obesity-and-diabetes-risk-300486303.html Tue, 11 Jul 2017 12:44:00 EDT en-US PR Newswire Association LLC.